Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-04-04 12:52 pm Purchase |
2024-03-15 | 13G | Ventyx Biosciences, Inc. VTYX |
Flynn James E | 3,542,000 5.030% |
3,542,000 (New Position) |
Filing History |
| 2024-03-22 5:44 pm Purchase |
2024-03-15 | 13D | BiomX Inc. PHGE |
Flynn James E | 611,010 11.060% |
611,010 (New Position) |
Filing History |
| 2024-03-15 4:37 pm Purchase |
2024-03-14 | 13D | Larimar Therapeutics, Inc. LRMR |
Flynn James E | 21,273,474 33.320% |
8,300 (+0.04%) |
Filing History |
| 2024-02-16 2:11 pm Purchase |
2024-02-16 | 13D | Larimar Therapeutics, Inc. LRMR |
Flynn James E | 21,265,174 34.820% |
4,291,539 (+25.28%) |
Filing History |
| 2024-02-15 5:20 pm Unchanged |
2024-02-13 | 13D | Larimar Therapeutics, Inc. LRMR |
Flynn James E | 16,973,635 39.200% |
0 (Unchanged) |
Filing History |
| 2024-02-12 5:34 pm Purchase |
2023-12-31 | 13G | Nuvalent, Inc. NUVL |
Flynn James E | 25,477,776 35.010% |
6,110 (+0.02%) |
Filing History |
| 2024-02-12 5:33 pm Sale |
2023-12-31 | 13G | Nuo Therapeutics, Inc. AURX |
Flynn James E | 2,183,164 5.160% |
-516,836 (-19.14%) |
Filing History |
| 2024-02-12 5:33 pm Purchase |
2023-12-31 | 13G | Kura Oncology, Inc. KURA |
Flynn James E | 5,312,733 7.150% |
938,689 (+21.46%) |
Filing History |
| 2024-02-12 5:32 pm Purchase |
2023-12-31 | 13G | Merus N.V. MRUS |
Flynn James E | 3,019,901 5.230% |
639,463 (+26.86%) |
Filing History |
| 2024-02-12 5:32 pm Purchase |
2023-12-31 | 13G | Deciphera Pharmaceuticals, Inc. DCPH |
Flynn James E | 5,788,024 7.190% |
1,160,714 (+25.08%) |
Filing History |
| 2024-02-12 5:31 pm Purchase |
2023-12-31 | 13G | Catalyst Pharmaceuticals, Inc. CPRX |
Flynn James E | 8,888,901 8.340% |
3,004,453 (+51.06%) |
Filing History |
| 2024-02-12 5:31 pm Sale |
2023-12-31 | 13G | Vigil Neuroscience, Inc. VIGL |
Flynn James E | 1,173,523 3.270% |
-878,487 (-42.81%) |
Filing History |
| 2024-02-12 5:31 pm Sale |
2023-12-31 | 13G | Singular Genomics Systems, Inc. OMIC |
Flynn James E | 250,496 6.830% |
-13,393 (-5.08%) |
Filing History |
| 2024-02-12 5:30 pm Sale |
2023-12-31 | 13G | Pulmonx Corporation LUNG |
Flynn James E | 6,009 0.020% |
-2,459,254 (-99.76%) |
Filing History |
| 2024-02-12 5:30 pm Purchase |
2023-12-31 | 13G | Prelude Therapeutics Incorporated PRLD |
Flynn James E | 4,133,000 9.850% |
910,310 (+28.25%) |
Filing History |
| 2024-02-12 5:29 pm Purchase |
2023-12-31 | 13G | Owens & Minor, Inc. OMI |
Flynn James E | 5,229,779 6.840% |
1,027,112 (+24.44%) |
Filing History |
| 2024-02-12 5:28 pm Purchase |
2023-12-31 | 13G | Oscar Health, Inc. OSCR |
Flynn James E | 11,246,820 5.890% |
709,329 (+6.73%) |
Filing History |
| 2024-02-12 5:27 pm Sale |
2023-12-31 | 13G | MALLINCKRODT PLC SHS MNKTQ |
Flynn James E | 1,281,233 6.500% |
-224,736 (-14.92%) |
Filing History |
| 2024-02-12 5:27 pm Purchase |
2023-12-31 | 13G | HilleVax, Inc. HLVX |
Flynn James E | 4,004,231 8.270% |
1,310,130 (+48.63%) |
Filing History |
| 2024-02-12 5:26 pm Purchase |
2023-12-31 | 13G | Enhabit, Inc. EHAB |
Flynn James E | 4,997,746 9.970% |
2,001,746 (+66.81%) |
Filing History |